Insmed Net Worth
Insmed Net Worth Breakdown | INSM |
Insmed Net Worth Analysis
Insmed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Insmed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Insmed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Insmed's net worth analysis. One common approach is to calculate Insmed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Insmed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Insmed's net worth. This approach calculates the present value of Insmed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Insmed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Insmed's net worth. This involves comparing Insmed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Insmed's net worth relative to its peers.
Enterprise Value |
|
To determine if Insmed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Insmed's net worth research are outlined below:
| The company reported the previous year's revenue of 305.21 M. Net Loss for the year was (749.57 M) with profit before overhead, payroll, taxes, and interest of 190.23 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (536.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Insmed Incorporated Stock Holdings Lifted by Jennison Associates LLC - MarketBeat |
Insmed Quarterly Good Will |
|
Insmed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Insmed Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Insmed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Insmed's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Macquarie Group Ltd | 2024-06-30 | 2.7 M | Franklin Resources Inc | 2024-06-30 | 2.7 M | Ameriprise Financial Inc | 2024-06-30 | 2.5 M | Suvretta Capital Management, Llc | 2024-06-30 | 2.5 M | Alliancebernstein L.p. | 2024-06-30 | 2.5 M | Artisan Partners Limited Partnership | 2024-06-30 | 2.5 M | William Blair Investment Management, Llc | 2024-09-30 | 2.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 2.3 M | Palo Alto Investors, Llc | 2024-06-30 | 2.1 M | Vanguard Group Inc | 2024-09-30 | 17.1 M | Blackrock Inc | 2024-06-30 | 14.3 M |
Follow Insmed's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.2 B.Market Cap |
|
Project Insmed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.70) | |
| Return On Capital Employed | (0.64) | (0.61) | |
| Return On Assets | (0.56) | (0.59) | |
| Return On Equity | 2.26 | 2.37 |
When accessing Insmed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Insmed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Insmed's profitability and make more informed investment decisions.
Evaluate Insmed's management efficiency
Insmed Inc has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.36) | (2.25) | |
| Tangible Book Value Per Share | (3.79) | (3.60) | |
| Enterprise Value Over EBITDA | (7.75) | (8.14) | |
| Price Book Value Ratio | (13.11) | (12.46) | |
| Enterprise Value Multiple | (7.75) | (8.14) | |
| Price Fair Value | (13.11) | (12.46) | |
| Enterprise Value | 746.7 M | 425.4 M |
Leadership at Insmed emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 36.5433 | Revenue 343 M | Quarterly Revenue Growth 0.182 | Revenue Per Share 2.206 | Return On Equity (8.91) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insmed Corporate Filings
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Insmed Earnings per Share Projection vs Actual
Insmed Corporate Management
| Mandy Fahey | Executive Communications | Profile | |
| Sara MBA | Chief Officer | Profile | |
| Nicole MBA | Chief Officer | Profile | |
| John Wise | Head VP | Profile | |
| Eleanor Barisser | Associate Relations | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.